Literature DB >> 23035204

In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

He Wang1, Meng Xiao, Sharon C-A Chen, Fanrong Kong, Zi-Yong Sun, Kang Liao, Juan Lu, Hai-Feng Shao, Yan Yan, Hong Fan, Zhi-Dong Hu, Yun-Zhuo Chu, Tie-Shi Hu, Yu-Xing Ni, Gui-Ling Zou, Ying-Chun Xu.   

Abstract

We conducted active, laboratory-based surveillance for isolates from patients with invasive infections across China from August 2009 to July 2010. DNA sequencing methods were used to define species, and susceptibility to fluconazole and voriconazole was determined by the Clinical and Laboratory Standards Institute M44-A2 disk diffusion method but using up-to-date clinical breakpoints or epidemiological cutoff values. Candida spp. made up 90.5% of the 814 yeast strains isolated, followed by Cryptococcus neoformans (7.7%) and other non-Candida yeast strains (1.7%). Bloodstream isolates made up 42.9% of the strains, isolates from ascitic fluid made up 22.1%, but pus/tissue specimens yielded yeast strains in <5% of the cases. Among the Candida isolates, Candida albicans was the most common species from specimens other than blood (50.1%) but made up only 23% of the bloodstream isolates (P < 0.001). C. parapsilosis complex species were the most common Candida isolates from blood (33.2%). Uncommon bloodstream yeast strains included Trichosporon spp., C. pelliculosa, and the novel species C. quercitrusa, reported for the first time as a cause of candidemia. Most (>94%) of the isolates of C. albicans, C. tropicalis, and the C. parapsilosis complex were susceptible to fluconazole and voriconazole, as were all of the Trichosporon strains; however, 12.2% of the C. glabrata sensu stricto isolates were fluconazole resistant and 17.8% had non-wild-type susceptibility to voriconazole. Seven C. tropicalis strains were cross-resistant to fluconazole and voriconazole; six were from patients in the same institution. Resistance to fluconazole and voriconazole was seen in 31.9% and 13.3% of the uncommon Candida and non-Candida yeast strains, respectively. Causative species and azole susceptibility varied with the geographic region. This study provided clinically useful data on yeast strains and their antifungal susceptibilities in China.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23035204      PMCID: PMC3502960          DOI: 10.1128/JCM.01130-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

Review 1.  Emerging opportunistic yeast infections.

Authors:  Marisa H Miceli; José A Díaz; Samuel A Lee
Journal:  Lancet Infect Dis       Date:  2011-02       Impact factor: 25.071

Review 2.  Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

Authors:  Michael A Pfaller; David Andes; Maiken C Arendrup; Daniel J Diekema; Ana Espinel-Ingroff; Barbara D Alexander; Steven D Brown; Vishnu Chaturvedi; Cynthia L Fowler; Mahmoud A Ghannoum; Elizabeth M Johnson; Cynthia C Knapp; Mary R Motyl; Luis Ostrosky-Zeichner; Thomas J Walsh
Journal:  Diagn Microbiol Infect Dis       Date:  2011-05-04       Impact factor: 2.803

Review 3.  Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

Authors:  M A Pfaller; D Andes; D J Diekema; A Espinel-Ingroff; D Sheehan
Journal:  Drug Resist Updat       Date:  2010-11-02       Impact factor: 18.500

4.  Differentiation of Candida glabrata, C. nivariensis and C. bracarensis based on fragment length polymorphism of ITS1 and ITS2 and restriction fragment length polymorphism of ITS and D1/D2 regions in rDNA.

Authors:  H Mirhendi; B Bruun; H C Schønheyder; J J Christensen; K Fuursted; B Gahrn-Hansen; H K Johansen; L Nielsen; J D Knudsen; M C Arendrup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-24       Impact factor: 3.267

5.  Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; G Isla; D Rodriguez; B Almirante; A Pahissa; J L Rodriguez-Tudela
Journal:  Med Mycol       Date:  2011-01-03       Impact factor: 4.076

6.  Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia.

Authors:  Maiken Cavling Arendrup; Sofia Sulim; Anette Holm; Lene Nielsen; Susanne Dam Nielsen; Jenny Dahl Knudsen; Niels Erik Drenck; Jens Jørgen Christensen; Helle Krogh Johansen
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

7.  Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China.

Authors:  Li-Na Guo; Meng Xiao; Fanrong Kong; Sharon C-A Chen; He Wang; Tania C Sorrell; Wei Jiang; Hong-Tao Dou; Ruo-Yu Li; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

8.  Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; G V Doern; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

9.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital.

Authors:  R Sabino; C Veríssimo; J Brandão; C Alves; H Parada; L Rosado; E Paixão; Z Videira; T Tendeiro; P Sampaio; C Pais
Journal:  Med Mycol       Date:  2010-03       Impact factor: 4.076

View more
  47 in total

1.  The discovery of potential phosphopantetheinyl transferase Ppt2 inhibitors against drug-resistant Candida albicans.

Authors:  Ling-Ning Meng; Jin-Yan Liu; Yu-Ting Wang; Shuai-Shuai Ni; Ming-Jie Xiang
Journal:  Braz J Microbiol       Date:  2020-06-18       Impact factor: 2.476

2.  Clinical Characteristics, Laboratory Identification, and In Vitro Antifungal Susceptibility of Yarrowia (Candida) lipolytica Isolates Causing Fungemia: a Multicenter, Prospective Surveillance Study.

Authors:  Ying Zhao; Jasper Fuk-Woo Chan; Chi-Ching Tsang; He Wang; Dawen Guo; Yuhong Pan; Yuling Xiao; Na Yue; Jonathan Hon-Kwan Chen; Susanna Kar-Pui Lau; Yingchun Xu; Patrick Chiu-Yat Woo
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

3.  A Comprehensive Evaluation of the Bruker Biotyper MS and Vitek MS Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Systems for Identification of Yeasts, Part of the National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study, 2012 to 2013.

Authors:  He Wang; Yan-Yan Fan; Timothy Kudinha; Zhi-Peng Xu; Meng Xiao; Li Zhang; Xin Fan; Fanrong Kong; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

4.  Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.

Authors:  Yu-Tsung Huang; Chia-Ying Liu; Chun-Hsing Liao; Kuei-Pin Chung; Wang-Huei Sheng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  Clinical and microbiological investigation of fungemia from four hospitals in China.

Authors:  Danfeng Dong; Zhen Li; Lihua Zhang; Cen Jiang; Enqiang Mao; Xuefeng Wang; Yibing Peng
Journal:  Mycopathologia       Date:  2015-02-27       Impact factor: 2.574

6.  Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-year (2010 to 2012) surveillance study.

Authors:  Wei Li; Yu-An Hu; Fang-Qiu Li; Li-Ning Shi; Hai-Feng Shao; Mei Huang; Ying Wang; Dan-Dan Han; Hong Liao; Chun-Fang Ma; Guo-Yong Zhang
Journal:  Mycopathologia       Date:  2015-01-15       Impact factor: 2.574

7.  Novel fluconazole derivatives with promising antifungal activity.

Authors:  Nishad Thamban Chandrika; Sanjib K Shrestha; Huy X Ngo; Kaitlind C Howard; Sylvie Garneau-Tsodikova
Journal:  Bioorg Med Chem       Date:  2017-12-17       Impact factor: 3.641

8.  Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience).

Authors:  Bilgul Mete; Esra Yerlikaya Zerdali; Gokhan Aygun; Nese Saltoglu; Ilker Inanc Balkan; Ridvan Karaali; Sibel Yildiz Kaya; Berna Karaismailoglu; Abdurrahman Kaya; Seval Urkmez; Gunay Can; Fehmi Tabak; Recep Ozturk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-15       Impact factor: 3.267

9.  Invasive Infections Due to Trichosporon: Species Distribution, Genotyping, and Antifungal Susceptibilities from a Multicenter Study in China.

Authors:  Li-Na Guo; Shu-Ying Yu; Po-Ren Hsueh; Abdullah M S Al-Hatmi; Jacques F Meis; Ferry Hagen; Meng Xiao; He Wang; Cinzia Barresi; Meng-Lan Zhou; G Sybren de Hoog; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

10.  Invasive Candidiasis in Brescia, Italy: Analysis of Species Distribution and Antifungal Susceptibilities During Seven Years.

Authors:  M A De Francesco; G Piccinelli; M Gelmi; F Gargiulo; G Ravizzola; G Pinsi; L Peroni; C Bonfanti; A Caruso
Journal:  Mycopathologia       Date:  2017-06-08       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.